Dr. Agarwal’s Health Care Limited announced strong unaudited consolidated financial results. Total income for 9M’FY2026 soared by 20.8% YoY to ₹1,548 Crores. IND-AS EBITDA grew by 23.6% YoY to ₹440 Crores, and PAT increased by 74.3% YoY to ₹118 Crores. The company’s network includes 272 facilities across 10 countries, solidifying its position as India’s largest eye care service chain.
Financial Performance Highlights
Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350) reported its unaudited consolidated financial results. Here’s a look at the key highlights for the quarter and nine months ended December 31, 2025 (Q3 FY2026):
- Total Income for 9M’FY2026: ₹1,548 Crores (up 20.8% YoY)
- IND-AS EBITDA for 9M’FY2026: ₹440 Crores (up 23.6% YoY)
- PAT for 9M’FY2026: ₹118 Crores (up 74.3% YoY)
Operational Highlights
As of December 31, 2025, the company’s network comprised 272 facilities, including 14 new centers added during the quarter (9 secondary, 5 primary). A total of 81,002 surgeries were performed in Q3 FY2026, representing an 11.2% YoY growth.
Revenue Breakdown
- Total Income: ₹540 Crores (up 21.9% YoY)
- Revenue from Operations: ₹530 Cr (up 23.0% YoY)
- India: ₹480 Cr (up 23.1% YoY)
- Mature Facilities: ₹405 Cr (up 37.8% YoY)
78.8% of revenue came from the sale of services, while 21.2% came from the sale of products.
Profitability Metrics
- EBITDA: ₹155 Cr (up 21.3% YoY) with EBITDA margins of 28.6%
- Profit after Tax: ₹44 Cr (up 54.5% YoY) with profit after tax margins of 8.1%
Corporate Actions
- Incorporation of a Wholly Owned Subsidiary in Ethiopia: Orbit Healthcare Services (Mauritius) Limited is incorporating a wholly owned subsidiary in Ethiopia.
- Shifting of Registered Office: The registered office and corporate office of the company has shifted to 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018, effective February 05, 2026.
- Amendment to Shareholders Agreement concerning Idearx Services Private Limited: Idearx ceases to be an ‘Associate’ to the Company.
Source: BSE
